HMG-CoA还原酶抑制剂与放射性肺损伤  

HMG-CoA reductase inhibitor and radiation-induced lung injury

作　　者：伊丽娜 董熠 姚颐[1,2] 宋启斌 Yi Lina;Dong Yi;Yao Yi;Song Qibin(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China;Hubei Provincial Research Center for Precision Medicine of Cancer,Wuhan 430200,China)

机构地区：[1]武汉大学人民医院肿瘤中心,湖北武汉430060 [2]湖北省肿瘤精准医学研究中心,湖北武汉430200

出　　处：《实用药物与临床》2022年第11期1049-1052,共4页Practical Pharmacy and Clinical Remedies

基　　金：吴阶平医学基金会临床科研专项。

摘　　要：放射性肺损伤(RILI)是胸部肿瘤放射治疗常见的并发症之一,是胸部放疗主要的剂量限制性因素,目前仍缺乏理想的治疗手段。既往研究表明,氧化应激及炎性因子在肺损伤和肺纤维化中发挥重要作用。作为羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,他汀类药物的多效性也体现在抗氧化应激、抗炎、抗纤维化等方面。本文将主要从机制上探讨他汀类药物对RILI潜在的治疗作用,为他汀类药物用于RILI的治疗提供线索和依据。Radiation-induced lung injury(RILI)is one of the common complications in the course of radiation therapy for patients with thoracic tumor, and is the main dose-limiting factor of thoracic radiotherapy.Currently, there is no ideal treatment method for this disease.Previous studies have shown that oxidative stress and inflammatory factors play an important role in pulmonary injury and fibrosis.As hydroxymethyl glutaryl-coenzyme A(HMG-CoA)reductase inhibitors, statins not only have lipid-lowering effects, but also have pleiotropic effects such as anti-oxidative stress, anti-inflammation and anti-fibrosis.In this review, the main mechanism of statins used for RILI are summarized, and the potential therapeutic value of statins in the treatment of RILI is introduced, providing clues and basis for the clinical treatment of RILI with statins.

关 键 词：HMG-COA还原酶抑制剂 放射性肺损伤 他汀类药物 

分 类 号：R818[医药卫生—放射医学]